GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a
GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.